StudyRareStudyRare

Gestational trophoblastic disease (Hydatidiform mole)

Log in to star

Last updated Nov 4, 2026

Log in to add personal notes on this page.

A patient at 10 weeks gestation has vaginal bleeding, a uterus larger than expected for dates, severe hyperemesis, and a markedly elevated β-hCG (>100,000 mIU/mL). Ultrasound shows a "snowstorm" intrauterine pattern with no embryo and bilateral theca lutein cysts. Suction D&C cytogenetics shows 46,XX of paternal-only origin: a complete hydatidiform mole.

A hydatidiform mole (Latin hydatis, "drop of water" + mola, "mass") is an abnormal pregnancy in which the chorionic villi swell into grape-like cysts, producing a cystic placenta in place of (or alongside) a viable fetus. Gestational trophoblastic disease (GTD) is the spectrum from these benign molar pregnancies to malignant trophoblastic neoplasia:

EntityBenign vs. malignant
Complete hydatidiform moleBenign but premalignant (~15-20% become persistent GTN)
Partial hydatidiform moleBenign (~1-5% persistent)
Persistent gestational trophoblastic neoplasia (GTN)Malignant; includes invasive mole, choriocarcinoma, placental site trophoblastic tumor (PSTT), epithelioid trophoblastic tumor (ETT)
ChoriocarcinomaMalignant; highly chemosensitive (single-agent methotrexate or EMA-CO)
Placental site trophoblastic tumorRare; resistant to chemotherapy → hysterectomy preferred

Sporadic moles arise from abnormal fertilization that leaves the conceptus with an excess of paternal genome; the rare familial recurrent form is AR (below).

FeatureComplete hydatidiform molePartial hydatidiform mole
KaryotypeDiploid (46,XX in ~90%; 46,XY in ~10%)Triploid (69,XXX, 69,XXY, or 69,XYY)
Origin (most)Empty ovum + duplication of one sperm (uniparental androgenetic disomy, "monospermic")Normal haploid ovum + dispermy (two sperm)
Origin (minority)Empty ovum + dispermy (still androgenetic)Rare: ovum + diploid sperm (failed meiosis)
Genome of originPaternal-only (androgenetic)One maternal set + two paternal sets
Embryo/fetal tissueAbsentPresent (often with triploid features: IUGR, syndactyly, anomalies)
Villous morphologyGeneralized hydropic edema, large grape-like villiFocal: mixed normal-sized and hydropic villi
Trophoblastic hyperplasiaDiffuse, circumferentialFocal
β-hCG levelMarkedly elevated (often >100,000)Modestly elevated
Risk of persistent GTN~15-20%~1-5%
Choriocarcinoma risk~2-3%<0.5%

Moles are disorders of genomic imprinting. Imprinted genes are expressed from only one parent's copy, a mark set by DNA methylation in egg or sperm, and the placenta expresses many of them. An excess of one parental genome over the other disturbs development of both the embryo and the placenta.

  • Complete mole: every chromosome is paternal, so maternally expressed genes are silent. One is CDKN1C, which makes the cell-cycle inhibitor p57KIP2 from the maternal allele only. Its absence makes complete moles p57-negative, and its role in contact inhibition of trophoblast stem cells suggests why trophoblast proliferates without control.
  • Partial mole: both genomes are present but unbalanced, usually an extra paternal set from dispermy. Paternal triploidy gives an abnormal placenta with relatively minor embryo changes, and the maternal allele keeps p57 staining positive.
  • Familial recurrent mole: the conceptus is diploid and biparental yet looks androgenetic. NLRP7 and KHDC3L are maternal-effect genes required in the oocyte. Moles from women with two defective alleles lose methylation at many regions normally methylated on the maternal allele; whether this causes the mole or follows abnormal early development is not clear. Because both genes are needed in the oocyte, ovum donation has produced live births.

A separate AR Mendelian disease: biallelic maternal variants in oocyte-restricted "maternal-effect" genes disrupt the female germline so that all the patient's pregnancies (regardless of partner) develop into complete moles, which are now biparental rather than androgenetic.

GeneNotes
NLRP7Most common (40-80% of affected individuals); subcortical maternal complex (SCMC) component
KHDC3LSecond most common; also SCMC
PADI6, MEI1, OOEP, TLE6Rare

Counseling for familial recurrent HM:

  • AR, recurrence ~25% per pregnancy in carrier couples; the additional issue is that the affected woman's all pregnancies tend to be molar, regardless of partner genotype, because of the maternal-effect mechanism
  • Egg/oocyte donation is the reproductive option that allows a successful pregnancy; donor oocytes lack the defective maternal-effect proteins
  • Testing NLRP7/KHDC3L in any woman with two or more consecutive molar pregnancies is recommended

Clinical presentation:

  • Vaginal bleeding (most common; passage of "grape-like" vesicles is pathognomonic)
  • Uterine size larger than dates (complete moles especially)
  • Severe hyperemesis gravidarum (hCG mimics TSH at supraphysiologic levels → can also produce biochemical hyperthyroidism)
  • Early-onset preeclampsia (<20 weeks gestation; outside the typical preeclampsia window, this is a major red flag for molar pregnancy)
  • Theca lutein ovarian cysts (large bilateral; from hCG hyperstimulation)
  • Markedly elevated β-hCG, especially in complete moles
  • Respiratory distress from trophoblastic embolization (rare, after evacuation)

Imaging:

  • Complete mole: classic "snowstorm" or "bunch of grapes" intrauterine pattern; no fetus; bilateral theca lutein cysts
  • Partial mole: enlarged placenta with cystic spaces; fetus may be present (often with triploid features); growth restriction
  • Quantitative β-hCG (markedly elevated in complete moles) plus pelvic ultrasound ("snowstorm" pattern, theca lutein cysts)
  • Histopathology of evacuated tissue is definitive; p57 immunohistochemistry distinguishes complete (p57-negative, no maternal genome) from partial moles (p57-positive)
  • Ploidy/genotyping resolves ambiguous cases (complete = diploid androgenetic; partial = triploid)
  • Baseline chest imaging if persistent GTN is suspected (lungs are the most common metastatic site)

Evacuation:

  • Suction dilation and curettage with sharp curettage
  • Send tissue for pathology (with p57 IHC) and ploidy
  • Anti-D immunoglobulin if Rh-negative
  • Hysterectomy is an option for women not desiring future fertility (reduces but does not eliminate persistent GTN risk)

Post-molar surveillance, the critical step:

  • Serial weekly β-hCG until undetectable for 3 consecutive weeks
  • Then monthly β-hCG for 6 months (some protocols 12 months)
  • Reliable contraception during the entire surveillance period (a new pregnancy raises hCG and obscures detection of persistent GTN)
  • Plateau or rise in β-hCG → diagnose persistent GTN → chemotherapy (single-agent methotrexate for low-risk; EMA-CO for high-risk per FIGO scoring)

Future pregnancies:

  • Recurrence risk after a single sporadic mole: ~1-2% (vs. background ~0.1%)
  • Recurrence after two moles: ~15-20%; test NLRP7/KHDC3L
  • First-trimester ultrasound recommended in subsequent pregnancies
  • Place placenta after delivery for pathology
  • "Early-onset severe preeclampsia (<20 weeks) + hyperemesis + uterine size > dates" should prompt evaluation for molar pregnancy
  • Sporadic complete moles are not heritable; recurrence after a single mole is mostly sporadic
  • Two or more consecutive molar pregnancies → think familial (NLRP7/KHDC3L) → offer egg donation counseling
  • Hyperthyroidism from hCG cross-reactivity is biochemical and resolves with evacuation; treat severe symptoms with beta-blockers, but propylthiouracil/methimazole rarely needed